Prothena Corp. Plc Aktie News

DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.

Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Particip...

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance.

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced that Oleg Nodelman will step down from Prothena's Board of Directors to create time to focus on existing and new endeavors.